Personalis, Inc. Hits New 52-Week High of $12.85 Amidst Remarkable Growth

Personalis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 12.85 on June 25, 2026. This achievement marks a remarkable increase from its 52-week low of USD 3.84, showcasing an impressive one-year performance of 853.79%, significantly outpacing the S&P 500's growth of 20.77% during the same period. With a market capitalization of USD 663 million, Personalis operates in a competitive industry characterized by innovation and rapid advancements. The company's financial metrics reflect its current standing, with a price-to-book ratio of 2.54. However, it is important to note that the company is currently loss-making, as indicated by its negative return on equity of -31.12% and a debt-to-equity ratio of -0.88. As Personalis, Inc. continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, this new high underscores its recent performance trajectory and market position.